GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (FRA:7R90) » Definitions » Notes Receivable

Qualigen Therapeutics (FRA:7R90) Notes Receivable : €1.17 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Notes Receivable?

Qualigen Therapeutics's Notes Receivable for the quarter that ended in Sep. 2024 was €1.17 Mil.

Qualigen Therapeutics's quarterly Notes Receivable stayed the same from Mar. 2024 (€0.00 Mil) to Jun. 2024 (€0.00 Mil) but then increased from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€1.17 Mil).


Qualigen Therapeutics Notes Receivable Historical Data

The historical data trend for Qualigen Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Notes Receivable Chart

Qualigen Therapeutics Annual Data
Trend Mar20 Dec21 Dec22 Dec23
Notes Receivable
- - - -

Qualigen Therapeutics Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 1.17

Qualigen Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Qualigen Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualigen Therapeutics Business Description

Traded in Other Exchanges
Address
5857 Owens Avenue, Suite 300, Carlsbad, CA, USA, 92008
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Qualigen Therapeutics Headlines

No Headlines